DraftColorado Rocky Mountain Health PlansPolicy CS016.O

Chelation therapy for heavy metal toxicity and overload

Medical policy governing the use of chelation therapy to treat heavy metal toxicity and overload conditions (e.g., iron, copper, lead, aluminum) for members of Colorado Rocky Mountain Health Plans except where state-specific policies apply.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyChelation therapy for heavy metal toxicity and overload

Policy CodePolicy CS016.O

Change TypeTitle and coverage rationale revised

Effective DateAug 1, 2025

Next Review Date

Key ActionObtain and document validated diagnostic testing showing metal intoxication and secure prior authorization when indicated.

SourceLink

POLICY UPDATE CHANGES

Policy title changed from 'Chelation Therapy for Non-Overload Conditions' to reflect that chelation for heavy metal toxicity and overload conditions is proven and medically necessary.

Content/language pertaining to the state of Louisiana was removed from the template.

ProvenChelation for heavy metal toxicity/overload

Not medically necessaryChelation for non-overload conditions

Multiple reviewsEvidence base

J‑codes listedProcedure/drug codes referenced

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

TACT/TACT2Pivotal EDTA trial

Coverage Criteria for Chelation Therapy

Unproven / Not Medically Necessary Indications

Not medically necessary / Unproven indications — Chelation therapy is considered NOT MEDICALLY NECESSARY or INVESTIGATIONAL when ANY of the following apply:

ANY of the following

Use of chelation therapy to treat chronic, progressive diseases that are not due to documented metal overload (examples include, but are not limited to: cardiovascular disease, atherosclerosis, diabetes, cancer, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, rheumatoid arthritis, chronic fatigue syndrome, chronic renal insufficiency, osteoarthritis, osteoporosis, schizophrenia, scleroderma, or vision disorders).
Evidence from systematic reviews and randomized trials does not support efficacy for these indications; see guideline positions and large trials (e.g., TACT, Cochrane reviews).
Use of chelation therapy to treat or 'remove' mercury alleged to originate from dental amalgam (dental amalgam) fillings.
No reliable evidence that dental amalgam causes systemic mercury toxicity in the general population; chelation for this purpose is not supported and may be harmful.
Use of chelation therapy based on unvalidated 'chelation challenge' or provocation urinary testing to diagnose heavy metal burden or justify chelation.
Professional societies (AAP, ACMT) recommend against chelation-challenge testing; it has no demonstrated prognostic value and may cause harm.
Use of chelation therapy to treat or cure autism spectrum disorder (ASD) or autism-related core symptoms.
Systematic reviews and randomized trial data show no benefit and document potential serious adverse events. The FDA has warned against such claims.
Use of EDTA/disodium EDTA chelation for the prevention or treatment of cardiovascular disease or stable ischemic heart disease outside of well-controlled clinical trials.
Major cardiology guidelines state EDTA is not approved for preventing or treating CVD and evidence is insufficient to support routine use.
Use of chelation therapy for removal of unspecified or unproven 'toxins' or metabolic byproducts where no validated diagnostic evidence of metal intoxication or overload exists.
Insufficient evidence of clinical benefit; inappropriate chelation risks adverse events (hypocalcemia, renal injury, electrolyte disturbances, allergic reactions).

Covered Chelation Regimens and Therapeutic Contexts

Regimen / Agent	Evidence Summary	Coverage Status
Deferiprone (DFP) — oral	Randomized, open-label noninferiority trials (Maggio et al. 2020; Kwiatkowski et al. 2022) demonstrate DFP is noninferior to deferasirox (DFX) for control of iron overload (serum ferritin, liver iron concentration, cardiac T2*). Reported AEs include gastrointestinal symptoms, transaminase elevations, neutropenia and rare agranulocytosis; overall safety profiles were comparable to DFX/DFO in trials.	covered
Deferasirox (DFX) — oral	DFX evaluated in randomized trials (TELESTO, Maggio et al.) and systematic reviews; TELESTO showed prolonged event-free survival in low–intermediate‑1 risk MDS with iron overload; DFX associated with renal, hepatic and GI AEs; comparative trials show similar efficacy to DFP in many populations.	covered
Deferoxamine (DFO) — parenteral (subcutaneous/infusion)	DFO remains an effective parenteral chelator; trials comparing DFP to parenteral DFO (Kwiatkowski et al. 2022) showed noninferiority of DFP versus DFO for LIC and cardiac T2*; DFO requires prolonged parenteral administration which may affect adherence.	covered
Combination oral regimens (DFP + DFX) — dual chelation	Systematic reviews (Salem et al. 2023) and single‑arm/comparative studies report that combined DFP+DFX reduces serum ferritin and liver iron, increases cardiac T2* in patients with inadequate response to monotherapy; adherence generally acceptable and serious AEs not consistently reported, though studies are limited by small sizes and variable quality.	covered

Line of Therapy

ICT in lower‑risk MDS: Consider iron chelation therapy in low‑ and intermediate‑1 risk myelodysplastic syndrome (MDS) patients with documented iron overload, recognizing evidence suggesting improved event‑free or overall survival in observational studies and supportive randomized trial data (e.g., TELESTO).documented iron overload in eligible MDS patients

ICT may be considered after individual benefit‑risk assessment; trial data show longer EFS with deferasirox versus placebo in TELESTO.

Procedure and Drug Codes

Referenced procedure/drug codesmixed

J0470	Injection, dimercaprol, per 100 mg.
J0600	Injection, edetate calcium disodium, up to 1,000 mg.
J0895	Injection, deferoxamine mesylate, 500 mg.
J3490	Unclassified drugs.
J3520	Edetate disodium, per 150 mg.
J8499	Prescription drug, oral, nonchemotherapeutic, NOS.
M0300	IV chelation therapy (chemical endarterectomy).
S9355	Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem

Provider Actions, Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for chelation therapy except when used for documented, validated metal intoxication or FDA‑approved indications. Requests for infusion services, J‑codes, or home infusion (e.g., J0470, J0600, J0895, J3520, M0300, S9355) should include prior authorization as appropriate under the member's benefit. FDA approval alone is informational; approval must align with the agent's labeled indications or recognized compendia references.

Affected HCPCS/J-codes include (but are not limited to): J0470, J0600, J0895, J3490, J3520, J8499; infusion and home infusion services: M0300, S9355.
Prior authorization applies to chelation infusions and related services unless the request documents validated metal intoxication diagnosed with appropriate biological samples.

Documentation Required

Required Diagnostic Workup and Documentation

Provide diagnostic documentation demonstrating accurate diagnosis of heavy metal intoxication prior to authorization. Documentation must include relevant clinical history, validated diagnostic testing on appropriate biological samples, and specific test results consistent with metal overload/intoxication.

Background and Evidence Summary

Chelation therapy is an established, evidence‑based treatment when there is a confirmed diagnosis of heavy‑metal overload (for example, iron, lead, copper, or aluminum) documented by validated testing. Appropriate agent selection, route of administration, monitoring for known risks (renal function, electrolytes, essential mineral levels), and informed consent are required to ensure expected benefit outweighs potential harms.

Key Definitions

Chelation therapy (agents, route, purpose)

DefinitionAdministration of naturally occurring or chemically designed molecules to bind and promote excretion of specific heavy metal toxins (eg, iron, copper, lead, aluminum, mercury).

Agents & routesAgents and routes vary by agent and clinical scenario (oral and parenteral agents; infusion or oral administration depending on the chelator).

Diagnostic requirementUsed only after an accurate diagnostic workup documenting metal overload using appropriate testing and reference values.

Non-overload condition

DefinitionClinical conditions in which acute or chronic heavy metal toxicity has not been demonstrated and for which chelation is hypothesized (but not proven) to provide benefit.

Examples

Policy Revision History

2026-04-01template updateLatest

Removed content and language pertaining to the state of Louisiana from the policy template.

2026-02-01administrative update

Removed reference link to retired state-specific policy version for Idaho (retired Feb. 1, 2026).

2025-11-01application update

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyChelation therapy for heavy metal toxicity and overload

Policy CodePolicy CS016.O

Change TypeTitle and coverage rationale revised

Effective DateAug 1, 2025

Next Review Date

Key ActionObtain and document validated diagnostic testing showing metal intoxication and secure prior authorization when indicated.

SourceLink

On This Page

History: exposure source, symptoms, timing, and clinical signs supporting intoxication.
Testing: validated laboratory testing (e.g., blood lead level, iron studies, serum ferritin, specific assays) or appropriate tissue testing with reference ranges and dates.
Interpretation: documentation that results meet established thresholds for clinically significant metal overload or intoxication and that chelation is indicated.

Denial Risk

Requests for Chelation to Treat Chronic Non‑Overload Conditions or Dental Amalgam Mercury

Requests to use chelation to treat chronic non‑overload diseases or to treat mercury exposure from dental amalgam fillings are not supported except with strong, case‑specific justification and validated testing showing clinically significant intoxication. Such requests will be subject to heightened review and may be denied.

Not supported: chelation for chronic, progressive non‑overload conditions (e.g., CVD, diabetes, Alzheimer's, autism).
Not supported: chelation solely for removal of mercury from dental amalgam without validated evidence of systemic mercury intoxication.

Denial Risk

Off‑Label / Non–FDA Indicated Use — Denial Risk

Off‑label or non–FDA‑indicated uses (for example, prevention or treatment of cardiovascular disease, autism, or other conditions not recognized in FDA labeling or accepted compendia) are considered investigational or not medically necessary and are subject to denial.

Coverage limited to FDA‑approved indications or uses supported by recognized drug compendia (e.g., AHFS, DrugDex).
Examples of likely denial triggers: chelation for CVD prevention/treatment, autism treatment claims, or other chronic non‑overload indications without compelling evidence.

Note

Clinical Trial Evidence and Agent Selection Guidance

Clinical trials have compared multiple chelating agents and regimens; evidence supports chelation for documented metal overload (e.g., deferiprone, deferasirox, deferoxamine for iron overload). However, trials do not establish routine use or superiority across all non‑overload indications. Agent selection should follow formulary guidance and recognized compendia.

Randomized studies (e.g., DFP vs DFO/DFX) demonstrate noninferiority for iron overload in transfusion‑dependent patients but require consideration of safety profiles and administration burden.
TACT and other cardiovascular trials do not support routine chelation for CVD; subgroup signals (e.g., diabetes) require replication before routine coverage.

Step Therapy

Step Therapy / Agent Selection

No formal step‑therapy sequencing is specified in this policy. Provider selection of chelating agent should align with the formulary, compendia recommendations, and clinical judgment, with documentation supporting the chosen agent and route of administration.

When multiple agents are clinically appropriate, document rationale (e.g., tolerability, route, comorbidities, prior adverse reactions).
If the plan imposes any step‑therapy edits outside this policy, follow the plan's specific pharmacy management rules.

Denial Risk

Denial Triggers for Off‑Label or Inadequately Documented Chelation

Denial triggers include insufficient or absent validated diagnostic testing, requests for chelation for unsupported indications, use of unvalidated 'chelation challenge' tests, or lack of documentation tying symptoms and exposures to measured, clinically significant metal burden.

Common denial reasons: missing blood/tissue test results, reliance on unproven challenge tests, or treating dental amalgam without evidence of systemic intoxication.
Ensure submitted records include laboratory values with reference ranges, dates, and clinician interpretation.

Includes proposed uses such as cardiovascular disease, rheumatoid arthritis, cancer, diabetes, neurodegenerative diseases, and autism spectrum disorder where metal overload is not documented.

Policy stanceChelation for non-overload conditions is considered unproven and not medically necessary; inappropriate use risks significant harms.

EDTA-based chelation (infusion context and trial references)

DefinitionInfusion-based chelation using edetate disodium (EDTA or Na2EDTA) administered as repeated IV infusions (eg, weekly infusion protocols used in trials).

Trial contextStudied in multicenter randomized trials (eg, TACT and a 2024 double-masked, placebo-controlled trial by Lamas et al.) in post-MI patients, including those with diabetes, comparing EDTA-based infusion to placebo with up to 40 weekly infusions.

Biochemical effectTrials demonstrated reductions in blood lead levels with EDTA-based infusions, though clinical event differences were not definitive in primary outcomes.

DMSA (dimercaptosuccinic acid) and trial context

DefinitionDimercaptosuccinic acid (DMSA) is an oral chelating agent evaluated to increase heavy metal excretion, particularly in pediatric studies.

Trial contextRandomized studies assessing multiple courses of oral DMSA in children who were high excreters of heavy metals did not show improvement in autism spectrum disorder symptoms and reported safety concerns (eg, hypocalcemia, renal impairment, death in reports).

Use considerationDMSA may be used for documented metal poisoning when indicated, but not for ASD or other non-overload conditions absent validated toxicity testing.

FDA-approved chelating agent

DefinitionA chelating drug that has received U.S. Food and Drug Administration approval for specific indications such as treatment of metal poisoning or iron overload, as listed in recognized drug compendia.

Coverage implicationUse of FDA‑approved chelating agents is limited to their labeled indications or indications supported by recognized compendia; FDA approval alone is informational and not a sole basis for coverage decisions.

Safety noteEven when used for appropriate, diagnosed intoxication, chelating drugs can cause significant adverse effects (eg, renal injury, hypocalcemia, mineral deficiencies), so indication and monitoring must be documented.

Added language clarifying the Medical Policy does not apply to Nebraska and North Carolina and referenced state-specific policy versions.

2025-09-01application update

Updated reference links to reflect current titles for state-specific policy versions for Kentucky and Louisiana.

2025-08-01title and coverage rationale change

Policy title changed from 'Chelation Therapy for Non-Overload Conditions' and coverage rationale updated to state that chelation for heavy metal toxicity and overload conditions is proven and medically necessary; supporting clinical evidence and references refreshed and prior policy version (CS016.N) archived.